Trial Profile
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bayer; Bayer HealthCare
- 15 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004072).
- 09 Jun 2009 Actual end date changed from Oct 2008 to Nov 2008 as reported by ClinicalTrials.gov.